Volume 18, Number 7—July 2012
Disseminated Microsporidiosis in an Immunosuppressed Patient
Highlight and copy the desired format.
|EID||Meissner EG, Bennett JE, Qvarnstrom Y, da Silva A, Chu EY, Tsokos M, et al. Disseminated Microsporidiosis in an Immunosuppressed Patient. Emerg Infect Dis. 2012;18(7):1155-1158. https://dx.doi.org/10.3201/eid1807.120047|
|AMA||Meissner EG, Bennett JE, Qvarnstrom Y, et al. Disseminated Microsporidiosis in an Immunosuppressed Patient. Emerging Infectious Diseases. 2012;18(7):1155-1158. doi:10.3201/eid1807.120047.|
|APA||Meissner, E. G., Bennett, J. E., Qvarnstrom, Y., da Silva, A., Chu, E. Y., Tsokos, M....Gea-Banacloche, J. (2012). Disseminated Microsporidiosis in an Immunosuppressed Patient. Emerging Infectious Diseases, 18(7), 1155-1158. https://dx.doi.org/10.3201/eid1807.120047.|
We report a case of disseminated microsporidiosis in a patient with multiple myeloma who had received an allogeneic stem cell transplant requiring substantial immunosuppression. The causative organism was identified as Tubulinosema acridophagus, confirming this genus of microsporidia as a novel human pathogen.
Microsporidia fungi are human pathogens known for causing diarrheal illness in persons infected with HIV; however, there is growing awareness of their involvement in other cases of host immunosuppression. A case of Tubulinosema sp. microsporidian myositis was recently reported in a patient with chronic lymphocytic leukemia (1). We describe a second case of disseminated microsporidiosis caused by a Tubulinosema sp. in an immunosuppressed patient who received an allogeneic stem cell transplant for multiple myeloma.
The patient was a 33-year-old woman with multiple myeloma. After receiving an autologous stem cell transplant (SCT), she experienced a relapse of disease and was enrolled in an experimental protocol of immunoablative chemotherapy, followed by hematopoietic SCT at the National Institutes of Health Clinical Center in Bethesda, Maryland (www.ClinicalTrials.gov identifier NCT00520130). Patients in this study are given a conditioning regimen of chemotherapy drugs (including fludarabine and cyclophosphamide), followed by prophylaxis against graft-versus-host disease (alemtuzumab and cyclosporine).
The patient received a 7/8 HLA-matched allogeneic peripheral blood SCT (with a single mismatch at the DRB1 locus) from an unrelated donor. Her clinical course was complicated by vancomycin-resistant Enterococcus faecium bacteremia, meningitis, and concomitant noncommunicating hydrocephalus and retinal hemorrhages. The bone marrow did not reconstitute, and 35 days after the initial transplant, the patient received a second SCT from the same donor after a conditioning regimen with antithymocyte globulin. Engraftment took place on day 49, 14 days after the second transplant. Progressive respiratory failure and pulmonary infiltrates had developed over the preceding week despite administration of broad-spectrum antimicrobial drugs. Results of a bronchoscopy on day 49 showed diffuse alveolar hemorrhage and did not identify a pathogen. Treatment with activated factor 7 and corticosteroids was given with some clinical improvement as well as improvement shown on chest radiograph.
A second bronchoalveolar lavage (BAL), performed on day 64, again showed diffuse alveolar hemorrhage and absence of pathogens. The patient received a second course of corticosteroids and activated factor 7. On day 77, an ophthalmologic examination was performed during a routine follow-up, and new retinal lesions suggestive of candida chorioretinitis were seen. Liposomal amphotericin B was substituted for prophylactic anidulafungin, and an intravitreal injection of amphotericin B was given for a subfoveal lesion.
At this time, the patient also had increasing hyperbilirubinemia and elevation of liver aminotransferases, together with diarrhea, abdominal distension, and new ascites. Graft-versus-host disease of the gut and liver was suspected. A colonoscopy on day 79 showed that, with the exception of 1 ulcer, the colonic mucosa appeared normal; biopsy samples showed nonspecific inflammation and a few apoptotic bodies. A liver biopsy and paracentesis were performed on day 85. Samples were stained with calcofluor white, which revealed yeast-like organisms 2–3 μm in diameter (Figure 1, panel A; Figure A1, panels A and B). The samples were also cultured for the presence of fungi, but results were negative.
Over the next 10 days, despite treatment with broad-spectrum antimicrobial drugs and corticosteroids, the patient had intermittent fever, continued elevation of liver enzymes, and progressive respiratory insufficiency with episodes of diffuse alveolar hemorrhage. Examination of BAL samples on days 90, 92, 96, and 97 was unrevealing. On day 96, multiple discrete, nonblanchable red macules and papules developed on the patient’s face, arms, legs, and trunk; the macules and papules were initially suggestive of disseminated candidiasis. Skin biopsy showed cysts mostly within the epidermis and follicular epithelium, similar to those seen previously in the liver biopsy sample and in ascitic fluid; these cysts featured closely packed, uniform, oval basophilic structures (Figure 1, panels B and C).
On day 96, diffuse alveolar hemorrhage recurred. BAL was performed, and staining with Diff-Quik (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA) and modified trichrome showed that the fluid samples were now positive for intracellular yeast-like forms. In retrospect, we determined that the BAL samples from day 90 also contained yeast-like forms, but they could not be identified at that time (Figure 1, panel D). Refractory hypoxemia developed, and the patient died on day 97 after the initial transplant. No postmortem examination was performed.
The remaining clinical specimens were subsequently examined to determine if the yeast-like forms were microsporidia. Warthin-Starry staining showed that all organisms in the skin and ascitic fluid were consistent with microsporidia (Figure 1, panel C; Figure A1, panel C). Similar organisms were identified in the BAL samples from days 90 and 96; spore size averaged 3.5 μm (range 3.3–3.9 μm) (Figure 1, panel D). Results of calcofluor white and modified acid-fast staining of the organisms were also positive, consistent with microsporidia.
Electron micrographs of skin and peritoneal fluid revealed microsporidian spores with features that were compatible with the genus Tubulinosema. Spores had a single layer of polar tubule or filament with 11–14 coils; the last 3 coils were clearly smaller in some spores (i.e., they had an anisofilar polar tubular arrangement) (Figure 1, panel E). The quality of the electron micrograph was limiting and did not allow visualization of the diplokaryon nucleus.
BAL samples were sent to the reference diagnostic laboratory for parasitology at the Centers for Disease Control and Prevention for molecular analysis. A nested PCR approach was applied, using the outer primers microFN18 (5′-CACCAGGTTGATTCTGCC-3′) and microR9 (5′-GTATGATCCTGCCACAGATTCTTCTAT-3′) and the inner primers Ta50f (5′-GGTTGATTCTGCCTGTTATATGT-3′) and Ta1300r (5′-GGACACATTCATCGTAACTTAGT-3′). Phylogenetic analysis of the resulting 1,246-bp sequence (GenBank accession no. JQ247017) revealed a high similarity to the small subunit ribosomal RNA gene from T. acridophagus (Figure 2), with only 1 nucleotide difference between the 2 sequences. Our final clinical diagnosis was disseminated T. acridophagus microsporidiosis with skin, liver, peritoneal, lung, and possibly chorioretinal involvement. Histopathology was notable for a paucity of inflammation around the organisms.
Along with another case of Tubulinosema sp. microsporidiosis (1), this case of disseminated microsporidiosis in an immunosuppressed SCT patient solidifies Tubulinosema sp. as a novel pathogen in immunosuppressed persons. By using molecular analysis, we characterized the microsporidian from the patient in our study to the species level (T. acridophagus).
Of 3 other reported cases of pulmonary microsporidiosis after SCT, 2 were in T cell–depleted patients (2,3), and the third was in a patient receiving high-dose methylprednisolone (1 g/m2) to treat graft-versus-host disease (4). The patient in our study was substantially immunosuppressed. She received alemtuzumab with her first allogeneic transplant and conditioning with antithymocyte globulin before her second transplant, resulting in significant in vivo T-cell depletion; she was also receiving adrenal corticosteroids. Because the patient had retinal changes suggestive of candidemia, we initially suspected that she had a disseminated infection. Although we did not identify the cause of these retinal changes, a case of endopthalmitis caused by microsporidia has been reported (5).
Microsporidia have only rarely been reported in the skin (6–8). The organisms we found in the skin and liver of the patient in our study were similar, providing the clue to the eventual postmortem diagnosis of disseminated microsporidiosis. This report reinforces the need to consider microsporidiosis as a life-threatening condition and a potential cause of diffuse alveolar hemorrhage after SCT (2,3), particularly in patients with extreme T-cell dysfunction.
Dr. Meissner is an infectious diseases fellow at National Institutes of Health. His research interests include HIV and hepatitis C co-infection.
We thank Daniel Fedorko for help with microbiological analysis and Govinda Visvesvara for help with interpretation of the microsporidia electron micrographs.
This research was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Allergy and Infectious Diseases and National Cancer Institute).
- Choudhary MM, Metcalfe MG, Arrambide K, Bern C, Visvesvara GS, Pieniazek NJ, Tubulinosema sp. microsporidian myositis in immunosuppressed patient. Emerg Infect Dis. 2011;17:1727–30.
- Ambrosioni J, van Delden C, Krause KH, Bouchuiguir-Wafa C, Nagy M, Passweg J, Invasive microsporidiosis in allogeneic haematopoietic SCT recipients. Bone Marrow Transplant. 2010;45:1249–51.
- Orenstein JM, Russo P, Didier ES, Bowers C, Bunin N, Teachey DT. Fatal pulmonary microsporidiosis due to Encephalitozoon cuniculi following allogeneic bone marrow transplantation for acute myelogenous leukemia. Ultrastruct Pathol. 2005;29:269–76.
- Kelkar R, Sastry PS, Kulkarni SS, Saikia TK, Parikh PM, Advani SH. Pulmonary microsporidial infection in a patient with CML undergoing allogeneic marrow transplant. Bone Marrow Transplant. 1997;19:179–82.
- Yoken J, Forbes B, Maguire AM, Prenner JL, Carpentieri D. Microsporidial endophthalmitis in a patient with acute myelogenous leukemia. Retina. 2002;22:123–5.
- Kester KE, Turiansky GW, McEvoy PL. Nodular cutaneous microsporidiosis in a patient with AIDS and successful treatment with long-term oral clindamycin therapy. Ann Intern Med. 1998;128:911–4.
- Kester KE, Visvesara GS, McEvoy P. Organism responsible for nodular cutaneous microsporidiosis in a patient with AIDS. Ann Intern Med. 2000;133:925.
- Visvesvara GS, Moura H, Leitch GJ, Schwartz DA, Xiao LX. Public health importance of Brachiola algerae (Microsporidia)—an emerging pathogen in humans. Folia Parasitol (Praha). 2005;52:83–94.
- Figure 1. . . . . Microsporidium detected in clinical specimens from a stem cell transplant patient who had undergone substantial immunosuppression. A) Calcofluor white–stained ascitic fluid (original magnification ×500). B)...
- Figure 2. . . . . Cladogram of Tubulinosematidae spp. based on small subunit ribosomal RNA gene sequences. Nosema apis was added as an outgroup. The phylogenetic tree was created by...
- Figure A1. . . . . Microsporidium detected in clinical specimens from a stem cell transplant patient who had undergone substantial immunosuppression. A) Gram-stained ascitic fluid (original magnification 1,000×). B) Hematoxylin...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Eric Meissner, NIH/NIAID, 10 Center Dr, Room 11N204, Bethesda, MD 20892, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 07, 2012
- Page last updated: June 22, 2012
- Page last reviewed: June 22, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)